Union Korea Pharm Past Earnings Performance
Past criteria checks 0/6
Union Korea Pharm's earnings have been declining at an average annual rate of -37.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 3.6% per year.
Key information
-37.5%
Earnings growth rate
-37.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 3.6% |
| Return on equity | -59.9% |
| Net Margin | -28.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Union Korea Pharm (KOSDAQ:080720) A Risky Investment?
Apr 23
Union Korea Pharm (KOSDAQ:080720) Is Carrying A Fair Bit Of Debt
Jan 27
What Percentage Of Union Korea Pharm Co., Ltd. (KOSDAQ:080720) Shares Do Insiders Own?
Dec 22The Union Korea Pharm (KOSDAQ:080720) Share Price Has Gained 38% And Shareholders Are Hoping For More
Nov 17Revenue & Expenses BreakdownBeta
How Union Korea Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 63,169 | -18,156 | 33,203 | 833 |
| 30 Sep 23 | 63,447 | -5,563 | 21,253 | 884 |
| 30 Jun 23 | 62,096 | -4,974 | 20,659 | 919 |
| 31 Mar 23 | 62,642 | -456 | 20,093 | 930 |
| 31 Dec 22 | 61,293 | -932 | 20,205 | 922 |
| 30 Sep 22 | 55,732 | -7,880 | 23,019 | 1,596 |
| 30 Jun 22 | 54,808 | -3,765 | 19,176 | 2,011 |
| 31 Mar 22 | 50,799 | -9,986 | 20,439 | 2,041 |
| 31 Dec 21 | 48,304 | -11,109 | 22,105 | 2,451 |
| 30 Sep 21 | 48,220 | -5,942 | 20,814 | 2,089 |
| 30 Jun 21 | 48,416 | -9,268 | 24,879 | 1,510 |
| 31 Mar 21 | 48,846 | -10,132 | 26,773 | 1,366 |
| 31 Dec 20 | 50,379 | -9,322 | 28,027 | 989 |
| 30 Sep 20 | 52,612 | -7,345 | 28,137 | 620 |
| 30 Jun 20 | 51,917 | -4,807 | 26,636 | 559 |
| 31 Mar 20 | 51,669 | -1,830 | 23,833 | 409 |
| 31 Dec 19 | 51,264 | 411 | 22,297 | 339 |
| 30 Sep 19 | 52,458 | 696 | 23,123 | 1,307 |
| 30 Jun 19 | 55,204 | 2,754 | 23,017 | 1,867 |
| 31 Mar 19 | 53,662 | 2,786 | 23,131 | 1,861 |
| 31 Dec 18 | 54,662 | 5,828 | 20,977 | 1,783 |
| 30 Sep 18 | 53,154 | 4,192 | 18,574 | 782 |
| 31 Dec 17 | 50,846 | 3,091 | 17,041 | 537 |
Quality Earnings: A080720 is currently unprofitable.
Growing Profit Margin: A080720 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A080720 is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.
Accelerating Growth: Unable to compare A080720's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A080720 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (34.6%).
Return on Equity
High ROE: A080720 has a negative Return on Equity (-59.87%), as it is currently unprofitable.